Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients

Area of Science:

• Endocrinology
• Genetics
• Pharmacogenomics

Background:

• Thyroid hormones (thyroxine/T4 and triiodothyronine/T3) are crucial for metabolism and development.
• Hypothyroidism, characterized by low T4 and T3, is often treated with levothyroxine (L-T4).
• L-T4 dosage adjustment is typically empirical, but genetic factors can affect treatment efficacy.

Purpose of the Study:

• To investigate the impact of genetic variations in thyroid hormone metabolism genes on L-T4 bioavailability.
• To evaluate the association between specific gene variants (DIO1, DIO2, TSHR, THR, UGT) and thyroid hormone levels in the Turkish population.
• To identify genetic markers that predict L-T4 treatment response.

Main Methods:

• Genotyping of key genes involved in thyroid hormone metabolism and transport.
• Analysis of associations between genetic variants and thyroid-stimulating hormone (TSH) levels.
• Evaluation of L-T4 treatment effectiveness in relation to identified genotypes.

Main Results:

• Specific variants (rs225014 and rs225015) in the DIO2 gene were significantly associated with TSH levels.
• The DIO2 rs225014 TT and rs225015 GG genotypes correlated with altered TSH levels.
• These findings suggest a genetic influence on thyroid hormone homeostasis and L-T4 response.

Conclusions:

• Genetic variations, particularly in DIO2, play a role in L-T4 treatment outcomes.
• Personalized hypothyroidism treatment may be achieved by considering patient genotypes.
• Lower L-T4 doses might be necessary for individuals with rs225014 TT and rs225015 GG genotypes for optimal therapeutic effect and reduced toxicity.